It appears that your browser has JavaScript disabled.

This Website requires your browser to be JavaScript enabled.

Please enable JavaScript and reload this page.

Attention: We have moved. Merck Millipore products are no longer available for purchase on MerckMillipore.com.

05-883 Sigma-AldrichAnti-tPA (Tissue Plasminogen Activator) Antibody, clone GMA-043

Detect tPA (Tissue Plasminogen Activator) using this Anti-tPA (Tissue Plasminogen Activator) Antibody, clone GMA-043 validated for use in ELISA & WB.

FDS (Fiches de données de sécurité), certificats d’analyse (CoA) et de qualité (CoQ), dossiers, brochures et autres documents disponibles.

FDS
CoA
Références bibliographiques

Research Category: Metabolism Research Sub-Category: Enzymes & Biochemistry Gene Symbol: PLAT, Reteplase, reteplase, T-PA, alteplase, DKFZp686I03148, Alteplase, tPA, TPA UniProt Number: P00750

Produits recommandés

Aperçu

Replacement Information

Offres spéciales

100% Performance Guaranteed

Tableau de caractéristiques principal

Species Reactivity	Key Applications	Host	Format	Antibody Type
H	ELISA, WB	M	Purified	Monoclonal Antibody

Description
Catalogue Number	05-883
Brand Family	Upstate
Trade Name	Upstate
Description	Anti-tPA (Tissue Plasminogen Activator) Antibody, clone GMA-043

References

Product Information
Format	Purified
Presentation	100 µg of protein G purified mouse IgG1 lyophilized from 10 mM NaH₂PO₄, 0.15 M NaCl, 1.0% mannitol, pH 7.4.
Quality Level	MQ100

Applications
Application	Detect tPA (Tissue Plasminogen Activator) using this Anti-tPA (Tissue Plasminogen Activator) Antibody, clone GMA-043 validated for use in ELISA & WB.
Key Applications	ELISA Western Blotting

Biological Information
Immunogen	Purified human tissue plasminogen activator (tPA)
Clone	clone GMA-043
Host	Mouse
Specificity	tPA
Isotype	IgG1
Species Reactivity	Human
Antibody Type	Monoclonal Antibody
Entrez Gene Number	NM_000930
Entrez Gene Summary	This gene encodes tissue-type plasminogen activator, a secreted serine protease which converts the proenzyme plasminogen to plasmin, a fibrinolytic enzyme. Tissue-type plasminogen activator is synthesized as a single chain which is cleaved by plasmin to a two chain disulfide linked protein. This enzyme plays a role in cell migration and tissue remodeling. Increased enzymatic activity causes hyperfibrinolysis, which manifests as excessive bleeding; decreased activity leads to hypofibrinolysis which can result in thrombosis or embolism. Alternative splicing of this gene results in multiple transcript variants encoding different isoforms.
Gene Symbol	PLAT Reteplase reteplase T-PA alteplase DKFZp686I03148 Alteplase tPA TPA
Purification Method	Protein G Purified
UniProt Number	P00750
UniProt Summary	FUNCTION: SwissProt: P00750 # Converts the abundant, but inactive, zymogen plasminogen to plasmin by hydrolyzing a single Arg-Val bond in plasminogen. By controlling plasmin-mediated proteolysis, it plays an important role in tissue remodeling and degradation, in cell migration and many other physiopathological events. Play a direct role in facilitating neuronal migration. SIZE: 562 amino acids; 62917 Da SUBUNIT: Heterodimer of chain A and chain B held by a disulfide bond. Binds to fibrin with high affinity. This interaction leads to an increase in the catalytic efficiency of the enzyme between 100-fold and 1000-fold, due to an increase in affinity for plasminogen. Similarly, binding to heparin increases the activation of plasminogen. Binds to annexin A2, cytokeratin-8, fibronectin and laminin. Binds to mannose receptor and the low- density lipoprotein receptor-related protein (LRP1); these proteins are involved in TPA clearance. Yet unidentified interactions on endothelial cells and vascular smooth muscle cells (VSMC) lead to a 100-fold stimulation of plasminogen activation. In addition, binding to VSMC reduces TPA inhibition by PAI-1 by 30-fold. Binds LRP1B; binding is followed by internalization and degradation. SUBCELLULAR LOCATION: Secreted, extracellular space. TISSUE SPECIFICITY: Synthesized in numerous tissues (including tumors) and secreted into most extracellular body fluids, such as plasma, uterine fluid, saliva, gingival crevicular fluid, tears, seminal fluid, and milk. DOMAIN: SwissProt: P00750 Both FN1 and one of the kringle domains are required for binding to fibrin. & Both FN1 and EGF-like domains are important for binding to LRP1. & The FN1 domain mediates binding to annexin A2. & The second kringle domain is implicated in binding to cytokeratin-8 and to the endothelial cell surface binding site. PTM: The single chain, almost fully active enzyme, can be further processed into a two-chain fully active form by a cleavage after Arg-310 catalyzed by plasmin, tissue kallikrein or factor Xa. & Differential cell-specific N-linked glycosylation gives rise to two glycoforms, type I (glycosylated at Asn-219) and type II (not glycosylated at Asn-219). The single chain type I glycoform is less readily converted into the two-chain form by plasmin, and the two-chain type I glycoform has a lower activity than the two- chain type II glycoform in the presence of fibrin. & N-glycosylation of Asn-152; the bound oligomannosidic glycan is involved in the interaction with the mannose receptor. & Characterization of O-linked glycan was studied in Bowes melanoma cell line.DISEASE:SwissProt: P00750 # Increased activity of TPA causes hyperfibrinolysis, with excessive bleeding as a consequence. & Defective release of TPA causes hypofibrinolysis, leading to thrombosis or embolism. SIMILARITY: Belongs to the peptidase S1 family. & Contains 1 EGF-like domain. & Contains 1 fibronectin type-I domain. & Contains 2 kringle domains. & Contains 1 peptidase S1 domain.
Molecular Weight	Mr 63kDa

Physicochemical Information

Dimensions

Materials Information

Toxicological Information

Safety Information according to GHS

Safety Information

Product Usage Statements
Quality Assurance	routinely evaluated by immunoblot on human tPA
Usage Statement	Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Storage and Shipping Information
Storage Conditions	stable 2 years at -20°C from date of shipment

Packaging Information
Material Size	100 µg

Transport Information

Supplemental Information

Specifications

Global Trade Item Number
Référence	GTIN
05-883	04053252670435

Documentation

Anti-tPA (Tissue Plasminogen Activator) Antibody, clone GMA-043 FDS

Titre
Fiche de données de sécurité des matériaux (FDS)

Anti-tPA (Tissue Plasminogen Activator) Antibody, clone GMA-043 Certificats d'analyse

Titre	Numéro de lot
Anti-tPA (Tissue Plasminogen Activator), clone GMA-043 (mouse monoclonal IgG1) - 2387482	2387482
Anti-tPA (Tissue Plasminogen Activator), clone GMA-043 (mouse monoclonal IgG1) - 2446690	2446690
Anti-tPA (Tissue Plasminogen Activator), clone GMA-043 (mouse monoclonal IgG1)	2981172
Anti-tPA (Tissue Plasminogen Activator), clone GMA-043 (mouse monoclonal IgG1)	3134099
Anti-tPA (Tissue Plasminogen Activator), clone GMA-043 (mouse monoclonal IgG1)	3117837
Anti-tPA (Tissue Plasminogen Activator), clone GMA-043 (mouse monoclonal IgG1) - 1956576	1956576
Anti-tPA (Tissue Plasminogen Activator), clone GMA-043 (mouse monoclonal IgG1) - 2030004	2030004
Anti-tPA (Tissue Plasminogen Activator), clone GMA-043 (mouse monoclonal IgG1) - 2219270	2219270
Anti-tPA (Tissue Plasminogen Activator), clone GMA-043 (mouse monoclonal IgG1) - 2283788	2283788
Anti-tPA (Tissue Plasminogen Activator), clone GMA-043 (mouse monoclonal IgG1) - 2302726	2302726

Références bibliographiques

Aperçu de la référence bibliographique	Nº PubMed
Tissue plasminogen activator as a modulator of neuronal survival and function Tsirka, Stella E Biochem Soc Trans, 30:222-5 (2002) 2002	12023855
Update on intravenous tissue plasminogen activator for acute stroke: from clinical trials to clinical practice Gladstone, D J and Black, S E CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 165:311-7 (2001) 2001	11517650
Tissue-type plasminogen activator: characteristics, applications and production technology. Rouf, S A, et al. Biotechnol. Adv., 14: 239-66 (1996) 1996 Afficher le résumé Plasminogen activators have immense clinical significance as thrombolytic agents for management of stroke and myocardial infarction. Tissue-type plasminogen activator (tPA) is generally preferred as being effective and safer than either urokinase or streptokinase type activators. Large-scale production of tPA became possible through groundbreaking developments in cell lines and bioprocess technology. Nevertheless, at thousands of dollars per treatment, tPA remains expensive. Enhancing cellular productivity and downstream product recovery through new approaches continue to be major challenges as discussed in this review. Recent clinical experience suggests the need for yet better fibrinolytic agents and attempts are underway to modify the tPA molecule to second generation products. Emerging trends in this field are outlined.	14537155

Produits & Applications associés

Catégories

Life Science Research > Antibodies and Assays > Primary Antibodies

Récemment consultés